| __timestamp | Veracyte, Inc. | Vertex Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 40786000 | 305409000 |
| Thursday, January 1, 2015 | 47876000 | 377080000 |
| Friday, January 1, 2016 | 52035000 | 432829000 |
| Sunday, January 1, 2017 | 55348000 | 496079000 |
| Monday, January 1, 2018 | 65276000 | 557616000 |
| Tuesday, January 1, 2019 | 82720000 | 658498000 |
| Wednesday, January 1, 2020 | 89118000 | 770456000 |
| Friday, January 1, 2021 | 181193000 | 840100000 |
| Saturday, January 1, 2022 | 174078000 | 944700000 |
| Sunday, January 1, 2023 | 184232000 | 1136600000 |
| Monday, January 1, 2024 | 1464300000 |
Unleashing insights
In the competitive world of biotechnology, operational efficiency is key. This analysis of Selling, General, and Administrative (SG&A) expenses from 2014 to 2023 offers a fascinating glimpse into the financial strategies of Vertex Pharmaceuticals Incorporated and Veracyte, Inc. Over this period, Vertex Pharmaceuticals has consistently outpaced Veracyte, with SG&A expenses growing by approximately 270%, reaching over $1.1 billion in 2023. In contrast, Veracyte's expenses have increased by about 350%, yet they remain significantly lower, peaking at around $184 million. This disparity highlights Vertex's aggressive investment in operational activities, likely supporting its expansive R&D and market reach. Meanwhile, Veracyte's more conservative spending reflects a focused approach, possibly prioritizing niche market penetration. As these companies continue to evolve, their SG&A trends offer valuable insights into their strategic priorities and market positioning.
Selling, General, and Administrative Costs: Pfizer Inc. vs Vertex Pharmaceuticals Incorporated
Breaking Down SG&A Expenses: Vertex Pharmaceuticals Incorporated vs Zoetis Inc.
Vertex Pharmaceuticals Incorporated and Teva Pharmaceutical Industries Limited: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Vertex Pharmaceuticals Incorporated and Opthea Limited
Who Generates More Revenue? Vertex Pharmaceuticals Incorporated or Veracyte, Inc.
Cost Management Insights: SG&A Expenses for Vertex Pharmaceuticals Incorporated and Ultragenyx Pharmaceutical Inc.
Vertex Pharmaceuticals Incorporated and Amneal Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Alpine Immune Sciences, Inc. and Veracyte, Inc.
PTC Therapeutics, Inc. or Veracyte, Inc.: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Veracyte, Inc. and ImmunityBio, Inc.
Cost Management Insights: SG&A Expenses for Veracyte, Inc. and Geron Corporation
Comparing SG&A Expenses: Veracyte, Inc. vs Taro Pharmaceutical Industries Ltd. Trends and Insights